Evidence map›Paper›PMID 26308386›Full record

ReviewMolecular endocrinology (Baltimore, Md.)2015

Minireview: Roles of Fibroblast Growth Factors 19 and 21 in Metabolic Regulation and Chronic Diseases.

Fangfang Zhang, Lechu Yu, Xiufei Lin, Peng Cheng, Luqing He, Xiaokun Li, Xuemian Lu, Yi Tan, Hong Yang, Lu Cai and 1 more

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Molecular endocrinology (Baltimore, Md.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed, 2 pooled it
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

70 citing papers in PubMed, 2 syntheses or guidelines pooled it, 134 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Detection of Multi-analytes Using Luminex Multiplex Bead Immunoassay.Methods in molecular biology (Clifton, N.J.) · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. FGF1 as a New Promising Therapeutic Target in Type 2 Diabetes: Advances in Research and Clinical Trials.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025
    Review
  19. Article
  20. Article

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Fangfang ZhangRuian Center of the Chinese-American Research Institute for Diabetic Complications (F.Z., L.Y., X.Lin, P.C., L.H., X.Lu, Y.T., H.Y., L.C., C.Z.), Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China 325200; Chinese-American Research Institute for Diabetic Complications (F.Z., X.Lin, P.C., L.H., X.Li, Y.T., L.C., C.Z.), Wenzhou Medical University, Wenzhou, Zhejiang, China 325035; School of Pharmaceutical Sciences (F.Z., X.Lin, P.C., L.H., X.Li, Y.T., C.Z.), Wenzhou Medical University, Wenzhou, Zhejiang, China 325035; and Department of Pediatrics (Y.T., L.C.), University of Louisville, Louisville, Kentucky 40202.
Lechu YuRuian Center of the Chinese-American Research Institute for Diabetic Complications (F.Z., L.Y., X.Lin, P.C., L.H., X.Lu, Y.T., H.Y., L.C., C.Z.), Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China 325200; Chinese-American Research Institute for Diabetic Complications (F.Z., X.Lin, P.C., L.H., X.Li, Y.T., L.C., C.Z.), Wenzhou Medical University, Wenzhou, Zhejiang, China 325035; School of Pharmaceutical Sciences (F.Z., X.Lin, P.C., L.H., X.Li, Y.T., C.Z.), Wenzhou Medical University, Wenzhou, Zhejiang, China 325035; and Department of Pediatrics (Y.T., L.C.), University of Louisville, Louisville, Kentucky 40202.
Xiufei LinRuian Center of the Chinese-American Research Institute for Diabetic Complications (F.Z., L.Y., X.Lin, P.C., L.H., X.Lu, Y.T., H.Y., L.C., C.Z.), Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China 325200; Chinese-American Research Institute for Diabetic Complications (F.Z., X.Lin, P.C., L.H., X.Li, Y.T., L.C., C.Z.), Wenzhou Medical University, Wenzhou, Zhejiang, China 325035; School of Pharmaceutical Sciences (F.Z., X.Lin, P.C., L.H., X.Li, Y.T., C.Z.), Wenzhou Medical University, Wenzhou, Zhejiang, China 325035; and Department of Pediatrics (Y.T., L.C.), University of Louisville, Louisville, Kentucky 40202.
Peng ChengRuian Center of the Chinese-American Research Institute for Diabetic Complications (F.Z., L.Y., X.Lin, P.C., L.H., X.Lu, Y.T., H.Y., L.C., C.Z.), Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China 325200; Chinese-American Research Institute for Diabetic Complications (F.Z., X.Lin, P.C., L.H., X.Li, Y.T., L.C., C.Z.), Wenzhou Medical University, Wenzhou, Zhejiang, China 325035; School of Pharmaceutical Sciences (F.Z., X.Lin, P.C., L.H., X.Li, Y.T., C.Z.), Wenzhou Medical University, Wenzhou, Zhejiang, China 325035; and Department of Pediatrics (Y.T., L.C.), University of Louisville, Louisville, Kentucky 40202.
Luqing HeRuian Center of the Chinese-American Research Institute for Diabetic Complications (F.Z., L.Y., X.Lin, P.C., L.H., X.Lu, Y.T., H.Y., L.C., C.Z.), Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China 325200; Chinese-American Research Institute for Diabetic Complications (F.Z., X.Lin, P.C., L.H., X.Li, Y.T., L.C., C.Z.), Wenzhou Medical University, Wenzhou, Zhejiang, China 325035; School of Pharmaceutical Sciences (F.Z., X.Lin, P.C., L.H., X.Li, Y.T., C.Z.), Wenzhou Medical University, Wenzhou, Zhejiang, China 325035; and Department of Pediatrics (Y.T., L.C.), University of Louisville, Louisville, Kentucky 40202.
Xiaokun LiRuian Center of the Chinese-American Research Institute for Diabetic Complications (F.Z., L.Y., X.Lin, P.C., L.H., X.Lu, Y.T., H.Y., L.C., C.Z.), Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China 325200; Chinese-American Research Institute for Diabetic Complications (F.Z., X.Lin, P.C., L.H., X.Li, Y.T., L.C., C.Z.), Wenzhou Medical University, Wenzhou, Zhejiang, China 325035; School of Pharmaceutical Sciences (F.Z., X.Lin, P.C., L.H., X.Li, Y.T., C.Z.), Wenzhou Medical University, Wenzhou, Zhejiang, China 325035; and Department of Pediatrics (Y.T., L.C.), University of Louisville, Louisville, Kentucky 40202.
Xuemian LuRuian Center of the Chinese-American Research Institute for Diabetic Complications (F.Z., L.Y., X.Lin, P.C., L.H., X.Lu, Y.T., H.Y., L.C., C.Z.), Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China 325200; Chinese-American Research Institute for Diabetic Complications (F.Z., X.Lin, P.C., L.H., X.Li, Y.T., L.C., C.Z.), Wenzhou Medical University, Wenzhou, Zhejiang, China 325035; School of Pharmaceutical Sciences (F.Z., X.Lin, P.C., L.H., X.Li, Y.T., C.Z.), Wenzhou Medical University, Wenzhou, Zhejiang, China 325035; and Department of Pediatrics (Y.T., L.C.), University of Louisville, Louisville, Kentucky 40202.
Yi TanRuian Center of the Chinese-American Research Institute for Diabetic Complications (F.Z., L.Y., X.Lin, P.C., L.H., X.Lu, Y.T., H.Y., L.C., C.Z.), Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China 325200; Chinese-American Research Institute for Diabetic Complications (F.Z., X.Lin, P.C., L.H., X.Li, Y.T., L.C., C.Z.), Wenzhou Medical University, Wenzhou, Zhejiang, China 325035; School of Pharmaceutical Sciences (F.Z., X.Lin, P.C., L.H., X.Li, Y.T., C.Z.), Wenzhou Medical University, Wenzhou, Zhejiang, China 325035; and Department of Pediatrics (Y.T., L.C.), University of Louisville, Louisville, Kentucky 40202.
Hong YangRuian Center of the Chinese-American Research Institute for Diabetic Complications (F.Z., L.Y., X.Lin, P.C., L.H., X.Lu, Y.T., H.Y., L.C., C.Z.), Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China 325200; Chinese-American Research Institute for Diabetic Complications (F.Z., X.Lin, P.C., L.H., X.Li, Y.T., L.C., C.Z.), Wenzhou Medical University, Wenzhou, Zhejiang, China 325035; School of Pharmaceutical Sciences (F.Z., X.Lin, P.C., L.H., X.Li, Y.T., C.Z.), Wenzhou Medical University, Wenzhou, Zhejiang, China 325035; and Department of Pediatrics (Y.T., L.C.), University of Louisville, Louisville, Kentucky 40202.
Lu CaiRuian Center of the Chinese-American Research Institute for Diabetic Complications (F.Z., L.Y., X.Lin, P.C., L.H., X.Lu, Y.T., H.Y., L.C., C.Z.), Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China 325200; Chinese-American Research Institute for Diabetic Complications (F.Z., X.Lin, P.C., L.H., X.Li, Y.T., L.C., C.Z.), Wenzhou Medical University, Wenzhou, Zhejiang, China 325035; School of Pharmaceutical Sciences (F.Z., X.Lin, P.C., L.H., X.Li, Y.T., C.Z.), Wenzhou Medical University, Wenzhou, Zhejiang, China 325035; and Department of Pediatrics (Y.T., L.C.), University of Louisville, Louisville, Kentucky 40202.
Chi ZhangRuian Center of the Chinese-American Research Institute for Diabetic Complications (F.Z., L.Y., X.Lin, P.C., L.H., X.Lu, Y.T., H.Y., L.C., C.Z.), Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China 325200; Chinese-American Research Institute for Diabetic Complications (F.Z., X.Lin, P.C., L.H., X.Li, Y.T., L.C., C.Z.), Wenzhou Medical University, Wenzhou, Zhejiang, China 325035; School of Pharmaceutical Sciences (F.Z., X.Lin, P.C., L.H., X.Li, Y.T., C.Z.), Wenzhou Medical University, Wenzhou, Zhejiang, China 325035; and Department of Pediatrics (Y.T., L.C.), University of Louisville, Louisville, Kentucky 40202.
Wenzhou Medical University · CNRuian People's Hospital · CN

Funding

Metabolomics study on the preventive mechanisms for LDR on diabetic nephropathyR01DK091338 · NIDDK · UNIVERSITY OF LOUISVILLE · PI CAI, LU · 2013 to 2014
$900k
NIDDK NIH HHS 1R01 DK091338-01A1NIDDK NIH HHS R01 DK091338
6 · The paper itself

Abstract

Fibroblast growth factor (FGF)19 and FGF21 are hormones that regulate metabolic processes particularly during feeding or starvation, thus ultimately influencing energy production. FGF19 is secreted by the intestines during feeding and negatively regulates bile acid synthesis and secretion, whereas FGF21 is produced in the liver during fasting and plays a crucial role in regulating glucose and lipid metabolism, as well as maintaining energy homeostasis. FGF19 and FGF21 are regarded as late-acting hormones because their functions are only used after insulin and glucagon have completed their actions. Although FGF19 and FGF21 are activated under different conditions, they show extensively functional overlap in terms of improving glucose tolerance, insulin sensitivity, weight loss, and lipid, and energy metabolism, particularly in pathological conditions such as diabetes, obesity, metabolic syndrome, and cardiovascular and renal diseases. Most patients with these metabolic diseases exhibit reduced serum FGF19 levels, which might contribute to its etiology. In addition, the simultaneous increase in serum FGF21 levels is likely a compensatory response to reduced FGF19 levels, and the 2 proteins concertedly maintain metabolic homeostasis. Here, we review the physiological and pharmacological cross talk between FGF19 and FGF21 in relation to the regulation of endocrine metabolism and various chronic diseases.

Indexed as

Chronic DiseaseMetabolismAdipose Tissue, WhiteFibroblast Growth FactorsHumansMetabolic Syndromefibroblast growth factor 21Fibroblast Growth Factors

Identifiers

PMID26308386
PMCPMC4588730
OpenAlexW1863321457

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.